Since the 1990s, opportunistic fungal infections have emerged as a substantial cause of
morbidity and mortality in profoundly immunocompromised patients. Hypercortisolaemic …

There is an increased awareness of the morbidity and mortality associated with fungal
infections caused by resistant fungi in various groups of patients. Epidemiological studies …

Posaconazale is a new triazole drug being investigated in phase III clinical trials for the
treatment and prevention of invasive fungal infections. In-vitro and in-vivo studies showed …

Aspergillus fumigatus causes invasive pulmonary aspergillosis (IPA). This disease is one of
the most life-threatening opportunistic infections in immunocompromised patients. The type …

The incidence of invasive aspergillosis is markedly increasing, and mortality remains dismal.
Previously there were only 2 antifungals with activity against Aspergillus, but over the last …

The very poor outcome of invasive fungal infections (IFI) in patients with haematological
malignancies or recipients of haematopoietic stem cell transplantation is largely attributed to …

Invasive aspergillosis has been studied in laboratory by the means of plethora of distinct
animal models. They were developed to address pathophysiology, therapy, diagnosis, or …

Invasive fungal infections have emerged as important causes of morbidity and mortality in
profoundly immunocompromised patients with cancer. Current treatment strategies for these …

The past, present and future of antimycotic combination therapy Vergangenheit, Gegenwart
und Zukunft der antimykotischen Kombina Page 1 mycoses 42, 355–370 (1999) Accepted …

Posaconazole is a novel lipophilic antifungal triazole that inhibits cytochrome P450-
dependent 14-α demethylase in the biosynthetic pathway of ergosterol. Inhibition of this …